These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort. Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J; Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116 [TBL] [Abstract][Full Text] [Related]
23. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections. Albin OR; Patel TS; Kaye KS Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359 [TBL] [Abstract][Full Text] [Related]
24. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam. Wenzler E; Scoble PJ Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557 [TBL] [Abstract][Full Text] [Related]
25. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. Tumbarello M; Trecarichi EM; De Rosa FG; Giannella M; Giacobbe DR; Bassetti M; Losito AR; Bartoletti M; Del Bono V; Corcione S; Maiuro G; Tedeschi S; Celani L; Cardellino CS; Spanu T; Marchese A; Ambretti S; Cauda R; Viscoli C; Viale P; J Antimicrob Chemother; 2015 Jul; 70(7):2133-43. PubMed ID: 25900159 [TBL] [Abstract][Full Text] [Related]
26. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Tiseo G; Falcone M; Leonildi A; Giordano C; Barnini S; Arcari G; Carattoli A; Menichetti F Open Forum Infect Dis; 2021 Jun; 8(6):ofab141. PubMed ID: 34189161 [TBL] [Abstract][Full Text] [Related]
27. Rapid diagnostics and ceftazidime/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy. Boattini M; Bianco G; Charrier L; Comini S; Iannaccone M; Almeida A; Cavallo R; De Rosa FG; Costa C Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):431-439. PubMed ID: 36806056 [TBL] [Abstract][Full Text] [Related]
28. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Falcone M; Bassetti M; Tiseo G; Giordano C; Nencini E; Russo A; Graziano E; Tagliaferri E; Leonildi A; Barnini S; Farcomeni A; Menichetti F Crit Care; 2020 Jan; 24(1):29. PubMed ID: 32000834 [TBL] [Abstract][Full Text] [Related]
30. An Update on Existing and Emerging Data for Meropenem-Vaborbactam. Shoulders BR; Casapao AM; Venugopalan V Clin Ther; 2020 Apr; 42(4):692-702. PubMed ID: 32147146 [TBL] [Abstract][Full Text] [Related]
31. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Shortridge D; Kantro V; Castanheira M Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Tumbarello M; Trecarichi EM; Corona A; De Rosa FG; Bassetti M; Mussini C; Menichetti F; Viscoli C; Campoli C; Venditti M; De Gasperi A; Mularoni A; Tascini C; Parruti G; Pallotto C; Sica S; Concia E; Cultrera R; De Pascale G; Capone A; Antinori S; Corcione S; Righi E; Losito AR; Digaetano M; Amadori F; Giacobbe DR; Ceccarelli G; Mazza E; Raffaelli F; Spanu T; Cauda R; Viale P Clin Infect Dis; 2019 Jan; 68(3):355-364. PubMed ID: 29893802 [TBL] [Abstract][Full Text] [Related]
34. Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae. Tiseo G; Galfo V; Riccardi N; Suardi LR; Pogliaghi M; Giordano C; Leonildi A; Barnini S; Falcone M Eur J Clin Microbiol Infect Dis; 2024 Feb; ():. PubMed ID: 38376634 [TBL] [Abstract][Full Text] [Related]
35. In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood. Papalini C; Sabbatini S; Monari C; Mencacci A; Francisci D; Perito S; Pasticci MB J Glob Antimicrob Resist; 2020 Dec; 23():4-8. PubMed ID: 32810638 [TBL] [Abstract][Full Text] [Related]
36. Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing Oliva A; Curtolo A; Volpicelli L; Cogliati Dezza F; De Angelis M; Cairoli S; Dell'Utri D; Goffredo BM; Raponi G; Venditti M Antibiotics (Basel); 2021 Jun; 10(7):. PubMed ID: 34199072 [TBL] [Abstract][Full Text] [Related]
37. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam. Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199 [TBL] [Abstract][Full Text] [Related]
38. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam. Tsivkovski R; Lomovskaya O Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015028 [TBL] [Abstract][Full Text] [Related]
39. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae. Sun D; Rubio-Aparicio D; Nelson K; Dudley MN; Lomovskaya O Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 29038260 [TBL] [Abstract][Full Text] [Related]
40. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae. Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]